2C-I

From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: 2C-I
2C-I
2C-I.svg
Chemical Nomenclature
Common names 2C-I
Substitutive name 2,5-Dimethoxy-4-iodophenethylamine
Systematic name 2-(4-Iodo-2,5-dimethoxyphenyl)ethan-1-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 2 - 5 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 30 mg
Heavy 30 mg +
Duration
Total 6 - 10 hours
Onset 15 - 45 minutes
Come up 45 - 90 minutes
Peak 3 - 5 hours
Offset 2 - 3 hours
After effects 6 - 24 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Tramadol
Stimulants
Lithium


2,5-Dimethoxy-4-iodophenethylamine (also known as 2C-I) is a psychedelic substance of the phenethylamine class. It is a member of the 2C-x family of psychedelic phenethylamines, all of which were derived from the systematic modification of the mescaline molecule.[1]

2C-I was first synthesized and investigated for human activity by Alexander Shulgin in 1976[2] and later described in his 1991 book PiHKAL ("Phenethylamines I Have Known and Loved"). Its PiHKAL entry notes it for being "very colorful and active" but without "feelings of insight, revelation, or progress toward the true meaning of the universe."[3] It first briefly gained some popularity in the late 1990s and early 2000s, where it was sold in several smart shops as a replacement for 2C-B following its scheduling in 1995.[4] It also has a history of being sold online as a research chemical before becoming scheduled.

2C-I is typically used recreationally for its psychedelic as well as moderate stimulating and entactogenic effects. It has been explored as a potential stimulant nootropic in the 1-8mg dosage range.[citation needed]

Little data exists about the pharmacological properties, metabolism, and toxicity of 2C-I, and it has a limited history of human use. 2C-I is sometimes confused for the analog 25I-NBOMe (an abbreviated form of 2C-I-NBOMe). It is highly advised to use harm reduction practices if using this substance.

Chemistry

Molecule.svg

This chemistry section is incomplete.

You can help by adding to it.

Generic structure of a phenethylamine molecule

2C-I, or 2,5-dimethoxy-4-iodophenethylamine, is a substituted phenethylamine comprising a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-I contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as an iodine atom attached to carbon R4 of the phenyl ring. 2C-I belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.[5]

Pharmacology

Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Further information: Serotonergic psychedelic

2C-I's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation.

Subjective effects

Disclaimer: The effects listed below are taken from the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy degree of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once, although higher doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Multi-sensory effects
Gears.svg

Transpersonal effects
Infinity4.svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

Ambulance2.png

This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
We also recommend that you conduct independent research and use harm reduction practices when using this substance.

The toxicity and long-term health effects of recreational 2C-I use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-I is a research chemical with very little history of human usage.

Anecdotal reports from those who have tried 2C-I suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance so as to ensure the accurate administration of the intended dose.

Tolerance and addiction potential

Although no formal studies have been conducted, it is not unreasonable to assume that as is the case with psychedelics in general, 2C-I is not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of 2C-I are built almost immediately after ingestion. After that, it takes about 3-5 days for the tolerance to be reduced to half and 7-10 days to be back at baseline (in the absence of further consumption). 2C-I presents cross-tolerance with all psychedelics, meaning that after the consumption of 2C-I all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when taken with other substances. The following lists some known dangerous combinations, but cannot be guaranteed to include all of them. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.

  • Tramadol - Tramadol lowers the seizure threshold[6] and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.[citation needed]
  • Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.[citation needed]
  • Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.[citation needed]

Legal status

  • Austria: 2C-I is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[7]
  • Canada: 2C-I is a schedule III controlled substance in Canada.[8]
  • Denmark: 2C-I is a controlled substance in Denmark.[9]
  • European Union: In December 2003, the European Council issued a binding order compelling all EU member states to ban 2C-I within three months.[citation needed]
  • Germany: 2C-I is controlled under Anlage I BtMG.[10] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[11]
  • Greece: 2C-I is a controlled substance in Greece.[9]
  • Ireland: 2C-I is a controlled substance in Ireland.[9]
  • Italy: 2C-I is a controlled substance in Italy.[9]
  • Latvia: 2C-I is a Schedule I controlled substance Latvia.[12]
  • The Netherlands: 2C-I is a controlled substance in the Netherlands.[9]
  • Poland: 2C-I is a controlled substance in Poland.[9]
  • Sweden: Sveriges riksdag added 2C-I to Schedule I ("substances, plant materials and fungi which normally do not have medical use") as a narcotic in Sweden as of March 16, 2004.[13]
  • Switzerland: Possession, production and sale is illegal.[14]
  • United Kingdom: 2C-I is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[15]
  • United States: As of July 9, 2012, 2C-I is a Schedule I substance in the U.S. under the Synthetic Drug Abuse Prevention Act of 2012, making possession, distribution and manufacture illegal.[9]

See also

External links

Community

References

  1. Alexander Shulgin - PiHKAL | http://www.erowid.org/library/books_online/pihkal/pihkal033.shtml
  2. Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p179 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf
  3. Shulgin, A., & Shulgin, A. (1991). IsomerDesign: "PiHKAL" - #33 - 2C-I. Retrieved Jan 22, 2018.
  4. http://in.reuters.com/article/us-drugs-overdose-idINTRE72I3QT20110319
  5. http://isomerdesign.com/PiHKAL/read.php?id=24
  6. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  7. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  8. Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)
  9. 9.0 9.1 9.2 9.3 9.4 9.5 9.6 Erowid.org, Legal Status of 2C-I
  10. https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html
  11. https://www.gesetze-im-internet.de/btmg_1981/__29.html
  12. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  13. http://www.lakemedelsverket.se/upload/lvfs/LVFS_2004-3.pdf
  14. http://web.archive.org/web/20170329020935/https://www.admin.ch/opc/de/classified-compilation/20101220/index.html
  15. United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made